The video provides a fundamental analysis of Pfizer (PFE). The analysis emphasizes the impact of policy changes in the pharmaceutical sector and the ongoing uncertainty due to changing tariff policies under the current administration. It highlights the gap between the calculated intrinsic value per share of Pfizer at $75.25, with the market price at $27.37. The analyst explicitly reiterates a 'buy' rating for Pfizer, appealing to long-term investors based on the expectation that the company will outlast current policy implementations. The analysis is based around the difference of the current market price and the calculated value of the company taking into account market volatility due to constant policy and tariff changes, and estimates a buy for Pfizer at 75.25